Akers Biosciences Inc (AKR)

 
This US company’s shares are traded by us as on the LSE. Income from them will not be treated as eligible for a reduced rate of tax. Learn more

AKR Share PerformanceMore

52 week high255.00 01/12/16
52 week low86.00 24/02/17
52 week change -55.00 (-37.93%)
4 week volume31,385 02/06/17

Media for (AKR)

Presenter: Ray, Akers, Co-Founder & Executive Chairman
29/07/2014
Presenter: Ray, Akers, Co-Founder & Executive Chairman
16/05/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Issue of Equity

Notification of an issue of equity shares e.g. offer for subscription/offer for sale/rights issue

Akers Biosciences revenue down

Akers Biosciences revealed that total revenue fell to $667,250 in the first quarter of 2017, down from $738,023 in the first qu...

1st Quarter Results

First quarter financial results

Akers Biosciences schedules interims

Akers Biosciences has said it will publish its financial results in the United Kingdom for the three months ended March 31...

Notice of Q1 Results

Notification of the date financial results will be published

Issue of Equity

Notification of an issue of equity shares e.g. offer for subscription/offer for sale/rights issue

Issue of Equity

Notification of an issue of equity shares e.g. offer for subscription/offer for sale/rights issue

Holding(s) in Company

Notification of major interests in shares

Equity Research (AKR)

Akers Biosciences Inc.
18/08/2016
Physiomics* (PYC.L) 0.04p £1.22m The computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials...
Akers Biosciences Inc.
11/08/2016
ValiRx (Val.L) 39p £4.37m The life science company, which focuses on clinical stage cancer therapeutic development has received regulatory approval for its VAL401 Phase IIB Clinical Trial in Georgia...

Latest discussion posts More

  • Re: RNS : new PIFA agreement

    Maybe turned the corner here
    30-Mar-2017
    Silveroil
  • RNS : new PIFA agreement

    Looks like a potentially lucrative agreement with a group of up to 300 New York hospitals to introduce the PIFA ...
    19-Dec-2016
    gretel
  • Exciting RNS just out

    Worth noting in particular that First Check are a subsidiary of the mighty Alere ...
    1-Dec-2016
    gretel

Users' HoldingsMore

Users who hold Akers Biosciences Inc also hold..
LLOYDS GRP.32%
ID:ISIN:GB00B142G99419%
NATIONAL GRID16%
BP16%
MORRISON (WM)12%

Codes & Symbols

ISINUS00973E1029
SymbolsAKR, LSE:AKR, AKR.L, AKR:LN, LON:AKR, XLON:AKR